RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Aurinia Pharmaceuticals Stock

Aurinia Pharmaceuticals P/S 2024

Aurinia Pharmaceuticals P/S

2.36

Ticker

AUPH

ISIN

CA05156V1022

WKN

A1W7D4

As of Oct 20, 2024, Aurinia Pharmaceuticals's P/S ratio stood at 2.36, a -57.32% change from the 5.53 P/S ratio recorded in the previous year.

The Aurinia Pharmaceuticals P/S history

Aurinia Pharmaceuticals Aktienanalyse

What does Aurinia Pharmaceuticals do?

Aurinia Pharmaceuticals Inc is a biopharmaceutical company that was founded in Canada in 1993. The company specializes in developing therapy options for autoimmune diseases, particularly the treatment of Lupus Nephritis, a condition where the immune system mistakenly attacks the body's own cells and damages the kidneys. Aurinia specializes in the field of biologic medications, which are based on proteins that naturally occur in the human body. These medications are used to modulate the immune system and "suppress" specific cells that trigger autoimmune diseases. Aurinia's main product is Voclosporin, an orally administered drug specifically developed for the treatment of Lupus Nephritis. Clinical trials have shown promising results, and Voclosporin received approval from the US FDA in 2020. Voclosporin is now successfully used in several countries worldwide. Aurinia also conducts research and development in other areas of autoimmune diseases. Another potential application is the treatment of Vogt-Koyanagi-Harada disease, a rare eye condition also attributed to autoimmune diseases. Aurinia's business model is based on developing new therapies that address the medical needs of patients with autoimmune diseases. The company focuses on close collaboration with medical professionals, patients and their families, as well as regulatory authorities. Aurinia has also formed partnerships with other companies and non-profit organizations to support its research and development and enhance access to its products in different countries. Aurinia's success relies on the extensive experience and expertise of its employees in biotechnological research, development and manufacturing of biologic medications, as well as its close partnerships with world-leading physicians in the field of autoimmune diseases. The company is committed to constantly improving the quality of its products and services to enhance patients' quality of life and effectively treat their disease. Overall, Aurinia Pharmaceuticals is a company dedicated to developing innovative therapies for autoimmune diseases, particularly for the treatment of Lupus Nephritis. The company strives to meet the medical needs of patients, their families, and medical professionals while also improving the entire ecosystem of medical care in this field. Aurinia's goal is to provide patients with better and more effective therapies and treatments to improve their health and well-being. Aurinia Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Aurinia Pharmaceuticals's P/S Ratio

Aurinia Pharmaceuticals's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Aurinia Pharmaceuticals's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Aurinia Pharmaceuticals's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Aurinia Pharmaceuticals’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Aurinia Pharmaceuticals stock

What is the price-to-earnings ratio of Aurinia Pharmaceuticals?

The price-earnings ratio of Aurinia Pharmaceuticals is currently 2.36.

How has the price-earnings ratio of Aurinia Pharmaceuticals changed compared to last year?

The price-to-earnings ratio of Aurinia Pharmaceuticals has increased by -57.32% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Aurinia Pharmaceuticals high compared to other companies?

Yes, the price-to-earnings ratio of Aurinia Pharmaceuticals is high compared to other companies.

How does an increase in the price-earnings ratio of Aurinia Pharmaceuticals affect the company?

An increase in the price-earnings ratio of Aurinia Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Aurinia Pharmaceuticals affect the company?

A decrease in the price-earnings ratio of Aurinia Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Aurinia Pharmaceuticals?

Some factors that influence the price-earnings ratio of Aurinia Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Aurinia Pharmaceuticals pay?

Over the past 12 months, Aurinia Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aurinia Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Aurinia Pharmaceuticals?

The current dividend yield of Aurinia Pharmaceuticals is .

When does Aurinia Pharmaceuticals pay dividends?

Aurinia Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Aurinia Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aurinia Pharmaceuticals located?

Aurinia Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aurinia Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aurinia Pharmaceuticals from 10/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/20/2024.

When did Aurinia Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/20/2024.

What was the dividend of Aurinia Pharmaceuticals in the year 2023?

In the year 2023, Aurinia Pharmaceuticals distributed 0 USD as dividends.

In which currency does Aurinia Pharmaceuticals pay out the dividend?

The dividends of Aurinia Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Aurinia Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Aurinia Pharmaceuticals

Our stock analysis for Aurinia Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aurinia Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.